Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi ...

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.

Amid a flurry of weight loss readouts, a fresh-on-the-scene startup has come out with Phase I results showing weight loss at day 36 on par with or better than competitors, with few gastrointestinal ...

Metsera plans to initiate a Phase 2b trial of MET-097 in Q4 2024, with data anticipated in the first half of 2025.

Metsera, the well-funded obesity biotech from Population Health Partners and ARCH Venture Partners, has unveiled its first ...

Weight loss with Ozempic or Wegovy can be effective, but expensive. Enter so-called GLP-1 supplements that have taken on the nickname “nature’s Ozempic.” They’re much cheaper than the ...

智通财经APP获悉，9月21日，中国国家药监局药品审评中心（CDE）官网最新公示，诺和诺德（NVO.US）1类新药NNC0519-0130注射液临床试验申请获得受理。

As the demand for GLP-1 drugs like Ozempic and Wegovy increases with consumers eager to shed pounds, the supplement industry is weighing in. Dietary supplement companies have been considering ways ...

Why Trust Us? GLP-1 receptor agonists like Ozempic and Wegovy have a lot of scientific data to support their use—and they can help people drop a lot of pounds. But is it possible to get the same ...

GLP-1 manufacturers are now offering significant discounts to entice payers and employers to cover their popular medications, The Wall Street Journal reported Sept. 20. In January, Eli Lilly ...

Wegovy and Ozempic use the prescription medication semaglutide to mimic the effects of the GLP-1 hormone. NurPhoto via Getty Images Why fork over thousands of dollars a month for prescription ...